GlassScriptPhysician profile
Xin Guan
NPI 1780918706
$10,465.43
in general payments reported to CMS, 2019-2025
27 companies · $2,421 in 2025
The $2,421 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,581 · 2022: $2,249 · 2023: $1,787 · 2024: $2,427 · 2025: $2,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,071 · Education: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,071.26 |
| Education | $564.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,202.74 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $1,195.11 | 2021-2025 | Ilumya, Winlevi |
| Lilly USA, LLC | $975.01 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $840.96 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $788.82 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $714.59 | 2022-2025 | Dupixent |
| Genzyme Corporation | $686.62 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $654.83 | 2021-2025 | Cabtreo, Jublia, Siliq |
| Amgen INC. | $558.91 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $506.43 | 2021-2025 | |
| Galderma Laboratories, L.P. | $456.32 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| E.R. Squibb & Sons, L.L.C. | $422.90 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $303.84 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $255.72 | 2022-2025 | |
| Epi Health, LLC | $167.32 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $113.29 | 2023-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $107.98 | 2024-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 | |
| Biofrontera INC. | $84.46 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $55.11 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $53.00 | 2021 | |
| Mayne Pharma Commercial LLC | $52.34 | 2021-2025 | |
| Organon LLC | $51.70 | 2025 | Vtama |
| Dermavant Sciences, INC. | $43.74 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.21 | 2025 | Spevigo |
| Allergan, INC. | $22.19 | 2021 | |
| Convatec INC. | $18.30 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xin Guan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.